Research & Academia
Breakthroughs, publications and the frontier of discovery.
Latest Research & Academia news
Cascade: How a 100-Million-Cell AI Project Could Transform Drug Discovery
Read at Kingy AI →Europe’s biotech frontier: Breakthrough potential and barriers
Read at Open Innovation --- Regione Lombardia →TeselaGen and Tec de Monterrey Partner on AI-Driven Research
Read at ACCESS Newswire →A*STAR, NUS launch lab to advance synthetic biology
Read at Singapore Economic Development Board (EDB) →Best Biotech Stocks to Buy for October 2026
Read at Zacks Investment Research →From the knowledge base
StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance
Shares of gene editing therapy companies mostly surged this past week on two growth catalysts: Data readouts at the European Society of Gene and Cell Therapy’s 33rd ESGCT Annual Congress, and the FDA's new draft guidance for personalized gene therapies.
How the NEXTY Awards open doors to valuable food service partnerships
Corporate food service providers offer bulk purchases, direct feedback and exposure to thousands of consumers. Here's how the NEXTY Awards can help you break in.
Anthropic’s one-person biotech buy; Jake Van Naarden’s dealmaking strategy; and more
Hello and welcome back to a spooky Halloween edition of Endpoints Weekly! Sorry to all the candy corn lovers out there, but just noting that they’re actually made with bug secretions. The Atlantic has all ...
Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure
According to the company, the funds will support the next phase of its growth in enabling autonomous science in labs and biopharmaceutical companies using its AI and robotics systems.
100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic
Parse Biosciences and Nomic Bio are partnering to create Cascade, a 100-million-cell multimodal dataset combining single-cell and proteomic data to advance AI-driven immune modeling, drug discovery, and therapeutic target identification.
Sanofi may seek higher European drug prices, not withhold launches, under Trump deal
While some of Europe’s biggest drugmakers have warned that President Donald Trump’s pricing policies could leave European patients waiting longer for new medicines, Sanofi is taking a different approach. ...